CTOs on the Move

Omicia

www.omicia.com

 
Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from personal genome sequences, to improve disease management and medical outcomes. Researchers and clinical diagnostic organizations use our solutions to analyze and identify the genetic basis of a variety of conditions, including childhood disease, cancer and cardiovascular disease. Opal™, the leading platform for fast, accurate and flexible genome analysis, enables clinicians, researchers and bioinformaticians alike to derive clinically relevant insights from genomic data. VAAST, our robust novel disease gene finder and variant scoring algorithm, is in use at ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.omicia.com
  • 1625 Clay Street 2nd Floor
    Oakland, CA USA 94612
  • Phone: 510.595.0800

Executives

Name Title Contact Details

Funding

Omicia raised $23M on 06/09/2016

Similar Companies

Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases.

Socati

Socati is the most advanced producer of THC-free full spectrum hemp. Purpose built for CBD infused products at global manufacturing scale, we combine expertise in seed genetics, proprietary extraction techniques and the most efficient purification systems available today. By integrating the entire supply chain, Socati is your partner in delivering to one of the most lucrative new product categories in history - non-psychoactive cannabinoid infusion.

Skagit Valley Hospital

Skagit Valley Hospital is a Mount Vernon, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avidity Biosciences

Avidity Biosciences, Inc.`s mission is to profoundly improve people`s lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity`s proprietary AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to target the root cause of diseases previously untreatable with RNA therapeutics. Avidity`s advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is currently in Phase 1/2 development with the ongoing MARINA™ and MARINA-OLE™ trials. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is currently in Phase 1/2 development with the FORTITUDE™ trial. AOC 1044 is designed for people with Duchenne muscular dystrophy (DMD) mutations amenable to exon 44 skipping and is currently in Phase 1/2 development with the EXPLORE44™ trial. AOC 1044 is the first of multiple AOCs the company is developing for DMD. Avidity is also broadening the reach of AOCs beyond muscle tissues through both internal discovery efforts and key partnerships as the company continues to deliver on the RNA revolution. Avidity is headquartered in San Diego, CA.

Harbor Biosciences

Harbor Biosciences, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.